AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2874032 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 2874032 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 31411963 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) plus prednisone
Number of subjects: 1082
Study 31411963 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (Control)
Number of subjects: 1082
Study 29161204 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) with carboplatin plus paclitaxel and 41.4-Gy radiotherapy followed by surgery
Number of subjects: 363
Study 29161204 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 363
Study 29691557 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser combined with AdperTM Easy One
Number of subjects: 30
Study 29691557 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser combined with AdperTM Easy One
Number of subjects: 30
Study 29691557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 25759746 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice (1.5 hours per day, 6 days a week for 5 months)
Number of subjects: 30
Study 25759746 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 23796235 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 394
Study 23796235 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 394
Study 23796235 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 394
Study 20683035 — intervention group
Group type: EXPERIMENTAL
Intervention: saracatinib 500 mg
Number of subjects: 56
Study 20683035 — intervention group
Group type: EXPERIMENTAL
Intervention: saracatinib 125 mg for 14 days
Number of subjects: 56
Study 20683035 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study 17702667 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented paper diaries (IPDs) used for self-monitoring during an 18-month weight-loss program.
Number of subjects: 64
Study 17702667 — intervention group
Group type: COMPARATOR
Intervention: Self-reported data on diary usage.
Number of subjects: 64
Study 16649859 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger hypothesis
Number of subjects: 0
Study 16649859 — intervention group
Group type: COMPARATOR
Intervention: Motivated reasoning hypothesis
Number of subjects: 0
Study 16649859 — intervention group
Group type: COMPARATOR
Intervention: Group differentiation hypothesis
Number of subjects: 0
Study 12680790 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for solitary metastasis in operable location and symptomatic mass effect
Number of subjects: 0
Study 12680790 — intervention group
Group type: COMPARATOR
Intervention: WBRT (Whole Brain Radiation Therapy) alone
Number of subjects: 0
Study 12680790 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + SRS (Stereotactic Radiosurgery)
Number of subjects: 0
Study 12680790 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS alone
Number of subjects: 0
Study 10639613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Number of subjects: 100
Study 10639613 — intervention group
Group type: COMPARATOR
Intervention: Progressive home exercise program
Number of subjects: 100
Study 8904876 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO) coupled to hydroxyethyl starch (HES-DFO)
Number of subjects: 0
Study 8904876 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Tf receptor antibody 42/6
Number of subjects: 0
Study 8904876 — intervention group
Group type: COMPARATOR
Intervention: Iron repletion by haemin
Number of subjects: 0
Study 8904876 — intervention group
Group type: COMPARATOR
Intervention: Iron chelation with DFO
Number of subjects: 0
Study 8904876 — intervention group
Group type: COMPARATOR
Intervention: Blockade of Tf-mediated iron uptake with anti-Tf receptor antibody 42/6
Number of subjects: 0
Study 1652265 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-adjusted solution of 2% mepivacaine with epinephrine
Number of subjects: 70
Study 1652265 — intervention group
Group type: COMPARATOR
Intervention: Standard commercial preparation of 2% mepivacaine with epinephrine
Number of subjects: 70
Study 1652265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 70
Study 7055082 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ppm SO2
Number of subjects: 8
Study 7055082 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ppm O3
Number of subjects: 8
Study 7055082 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ppm SO2 plus 0.4 ppm O3
Number of subjects: 8
Study 7055082 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 8
Study 31823433 — intervention group
Group type: EXPERIMENTAL
Intervention: GO blended RelyX (RXGO)
Number of subjects: 12
Study 31823433 — intervention group
Group type: COMPARATOR
Intervention: RelyX (RX)
Number of subjects: 12
Study 31823433 — intervention group
Group type: COMPARATOR
Intervention: Monobond-S (MB)
Number of subjects: 12
Study 31823433 — intervention group
Group type: EXPERIMENTAL
Intervention: GO blended Monobond-S (MBGO)
Number of subjects: 12
Study 28993335 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz in combination with Zidovudine-Lamivudine
Number of subjects: 0
Study 28993335 — intervention group
Group type: COMPARATOR
Intervention: Maraviroc in combination with Zidovudine-Lamivudine
Number of subjects: 0
Study 25988766 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES) 3mL·kg(‐1) body mass of a 6% CES every 20 min during exercise
Number of subjects: 8
Study 25988766 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (PL) every 20 min during exercise
Number of subjects: 8
Study 25988766 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 8
Study 25988766 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (PL)
Number of subjects: 8
Study 23681159 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking as usual
Number of subjects: 25
Study 23681159 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight abstinence from smoking
Number of subjects: 25
Study 23681159 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward trial blocks
Number of subjects: 25
Study 23681159 — intervention group
Group type: EXPERIMENTAL
Intervention: No-reward trial blocks
Number of subjects: 25
Study 21440749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (TAC; 4-6 ng/mL)
Number of subjects: 58
Study 21440749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL; 6-10 ng/mL)
Number of subjects: 58
Study 21440749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (TAC)
Number of subjects: 58
Study 21440749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 58
Study 19811343 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 48
Study 19811343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16924980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofilled resin composite (Filtek Supreme)
Number of subjects: 42
Study 16924980 — intervention group
Group type: COMPARATOR
Intervention: Microhybrid composite (Pyramid, Esthet‐X, Tetric Ceram)
Number of subjects: 42
Study 15868872 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue fixation
Number of subjects: 213
Study 11704395 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg eniporide
Number of subjects: 1389
Study 11704395 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg eniporide
Number of subjects: 1389
Study 11704395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1389
Study 11704395 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall eniporide treatment
Number of subjects: 1389
Study 11704395 — intervention group
Group type: EXPERIMENTAL
Intervention: Late reperfusion (>4 h)
Number of subjects: 1389
Study 9462186 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic triglyceride milk formula containing Betapol with 74% palmitate in the 2-position
Number of subjects: 24
Study 7481086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fair Play for Kids curriculum during physical education only
Number of subjects: 452
Study 7481086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fair Play for Kids curriculum during all school subjects
Number of subjects: 452
Study 7481086 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 452
Study 2184847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 820
Study 2184847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 820
Study 7191310 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (3 x 30 mg/d)
Number of subjects: 40
Study 7191310 — intervention group
Group type: COMPARATOR
Intervention: Indometacin (3 x 50 mg/d)
Number of subjects: 40
Study 30606140 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic risk assessment during pregnancy with emphasis on identification of non‐medical risk factors and client‐tailored approach during pregnancy and postpartum.
Number of subjects: 12
Study 30606140 — intervention group
Group type: COMPARATOR
Intervention: Systematic risk assessment during pregnancy only.
Number of subjects: 12
Study 30606140 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-tailored approach during pregnancy and postpartum.
Number of subjects: 12
Study 27749321 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 198
Study 27749321 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 198
Study 27749321 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day vs 20 mg/day
Number of subjects: 198
Study 27749321 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin administration
Number of subjects: 198
Study 26407654 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 5mg/day
Number of subjects: 149
Study 26407654 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine 20mg/day
Number of subjects: 149
Study 26407654 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine 20mg/day + Simvastatin 20mg/day
Number of subjects: 149
Study 26407654 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 5mg/day + Simvastatin 20mg/day
Number of subjects: 149
Study 26407654 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg/day (added to both treatments)
Number of subjects: 149
Study 23943839 — intervention group
Group type: EXPERIMENTAL
Intervention: Heaviness of Smoking Index (HSI)
Number of subjects: 1050
Study 23943839 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cotinine
Number of subjects: 1050
Study 22288485 — intervention group
Group type: EXPERIMENTAL
Intervention: FMUD+AM (375 mg amoxicillin plus 250 mg metronidazole for 7 days)
Number of subjects: 24
Study 22288485 — intervention group
Group type: COMPARATOR
Intervention: FMUD (placebo)
Number of subjects: 24
Study 22288485 — intervention group
Group type: EXPERIMENTAL
Intervention: FMUD+AM
Number of subjects: 24
Study 22288485 — intervention group
Group type: COMPARATOR
Intervention: FMUD
Number of subjects: 24
Study 20670329 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-conducted motivational intervention with a 10-day booster
Number of subjects: 853
Study 20670329 — intervention group
Group type: COMPARATOR
Intervention: Standard assessed control (AC)
Number of subjects: 853
Study 20670329 — intervention group
Group type: COMPARATOR
Intervention: Minimally assessed control (MAC)
Number of subjects: 853
Study 20670329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both I and AC groups
Number of subjects: 853
Study 17400833 — intervention group
Group type: EXPERIMENTAL
Intervention: Position of power
Number of subjects: 0
Study 17400833 — intervention group
Group type: EXPERIMENTAL
Intervention: Power motivation under unstable dominance hierarchy
Number of subjects: 0
Study 17400833 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrevocable power with no bearing on choices
Number of subjects: 0
Study 15767216 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 8
Study 15767216 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 8
Study 15767216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 8
Study 12463106 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (200 IU/day)
Number of subjects: 70
Study 12463106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9421099 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole orally once a day for 5 days
Number of subjects: 10
Study 9421099 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally once a day for 5 days
Number of subjects: 10
Study 7984564 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologic studies in 15 histiocytosis X patients
Number of subjects: 24
Study 3433371 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus weekly low-dose cisplatin
Number of subjects: 54
Study 3433371 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 54
Study 28391730 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling group (didactic HPV presentation + factsheet)
Number of subjects: 121
Study 28391730 — intervention group
Group type: COMPARATOR
Intervention: Leaflet group (written HPV factsheet)
Number of subjects: 121
Study 28391730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (leaflet and counselling)
Number of subjects: 121
Study 27840834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay Health Trainer (LHT) intervention
Number of subjects: 0
Study 27840834 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24854966 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorder (AUD)
Number of subjects: 763
Study 24854966 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational factors (frequency of having sex with a partner in a shebeen, tavern, or bottle store)
Number of subjects: 763
Study 22986144 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (125 mg/m² IV over 30 minutes on days 1, 8, and 15 of each 28-day cycle)
Number of subjects: 35
Study 22986144 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Number of subjects: 35
Study 20151129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (8 mg)
Number of subjects: 210
Study 20151129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 18516888 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 1% hyperbaric lidocaine 1 ml (10 mg) (group L)
Number of subjects: 80
Study 18516888 — intervention group
Group type: COMPARATOR
Intervention: Propofol general anesthesia (1.0 mg x kg(‐1) injected at 180 mg x kg(‐1) x hr(‐1) followed by continuous infusion at 8 mg x kg(‐1) x hr(‐1) (group P)
Number of subjects: 80
Study 18516888 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 1% hyperbaric lidocaine (group L)
Number of subjects: 80
Study 18516888 — intervention group
Group type: COMPARATOR
Intervention: Propofol general anesthesia (group P)
Number of subjects: 80
Study 16103847 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video plus usual care
Number of subjects: 405
Study 16103847 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 405
Study 11790169 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg, twice daily for 6 months)
Number of subjects: 239
Study 11790169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 6 months)
Number of subjects: 239
Study 10086433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (stimulus control, sleep restriction, sleep hygiene, and cognitive therapy)
Number of subjects: 78
Study 10086433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (temazepam)
Number of subjects: 78
Study 10086433 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioral and pharmacological therapy
Number of subjects: 78
Study 10086433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 7669238 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilled cabbage leaves
Number of subjects: 28
Study 7669238 — intervention group
Group type: COMPARATOR
Intervention: Room temperature cabbage leaves
Number of subjects: 28
Study 1922223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg slow-release preparation every 8 hours)
Number of subjects: 21
Study 1922223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1922223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 21
Study 6214058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh donor specific transfusions (DST)
Number of subjects: 18
Study 6214058 — intervention group
Group type: COMPARATOR
Intervention: Stored donor specific transfusions (DST)
Number of subjects: 18
Study 30300047 — intervention group
Group type: COMPARATOR
Intervention: 3 mg·kg‐1 caffeine
Number of subjects: 15
Study 30300047 — intervention group
Group type: COMPARATOR
Intervention: 1 or 2 mg·kg‐1 caffeine
Number of subjects: 15
Study 29317362 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion Block before Pulsed Radiofrequency (DRG-PRF)
Number of subjects: 60
Study 29317362 — intervention group
Group type: COMPARATOR
Intervention: Dorsal Root Ganglion Pulsed Radiofrequency (DRG-PRF) without DRG block
Number of subjects: 60
Study 29317362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness comparison
Number of subjects: 60
Study 26560094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based program of home-delivered care (up to eight visits over 1 year)
Number of subjects: 236
Study 26560094 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 236
Study 25131925 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure Management Program (HFMP)
Number of subjects: 160
Study 25131925 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment by general practitioner (GP)
Number of subjects: 160
Study 20708393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapeutic lifestyle changes (TLSC) program
Number of subjects: 150
Study 20708393 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical care (control group, CG)
Number of subjects: 150
Study 19011145 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterex Diabetic
Number of subjects: 14
Study 19011145 — intervention group
Group type: COMPARATOR
Intervention: Glucerna SR
Number of subjects: 14
Study 17710288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride‐releasing elastomeric ligature ties (Fluor‐I‐Ties, Ortho Arch Co. Inc., USA)
Number of subjects: 40
Study 17710288 — intervention group
Group type: COMPARATOR
Intervention: Conventional elastomeric ligature ties (D. Morelli, Brazil)
Number of subjects: 40
Study 15085512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) at the medial orbital rim
Number of subjects: 62
Study 15085512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) at the lateral orbital rim
Number of subjects: 62
Study 15085512 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CCT) as reference method
Number of subjects: 62
Study 12324292 — intervention group
Group type: COMPARATOR
Intervention: Threonine intake of 7 mg x kg(‐1) x d(‐1)
Number of subjects: 16
Study 12324292 — intervention group
Group type: EXPERIMENTAL
Intervention: Threonine intake of 11 mg x kg(‐1) x d(‐1)
Number of subjects: 16
Study 12324292 — intervention group
Group type: EXPERIMENTAL
Intervention: Threonine intake of 15 mg x kg(‐1) x d(‐1)
Number of subjects: 16
Study 12324292 — intervention group
Group type: EXPERIMENTAL
Intervention: Threonine intake of 19 mg x kg(‐1) x d(‐1)
Number of subjects: 16
Study 12324292 — intervention group
Group type: EXPERIMENTAL
Intervention: Threonine intake of 22 mg x kg(‐1) x d(‐1)
Number of subjects: 16
Study 12324292 — intervention group
Group type: EXPERIMENTAL
Intervention: Threonine intake of 27 mg x kg(‐1) x d(‐1)
Number of subjects: 16
Study 9647135 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high dose)
Number of subjects: 116
Study 9647135 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (low dose)
Number of subjects: 116
Study 9647135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump prime only
Number of subjects: 116
Study 9647135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 7856808 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional knee brace
Number of subjects: 6
Study 7856808 — intervention group
Group type: COMPARATOR
Intervention: Unbraced leg
Number of subjects: 6
Study 2813660 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (30 mg)
Number of subjects: 9
Study 2813660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (30 mg)
Number of subjects: 9
Study 2813660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 883811 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) 960 mg TMP and 4800 mg SMZ
Number of subjects: 15
Study 883811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29951886 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (47.5 mg once daily)
Number of subjects: 100
Study 29951886 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg once daily)
Number of subjects: 100
Study 27802097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxandrolone (Ox) 0.06 mg/kg/d for 2 years
Number of subjects: 93
Study 27802097 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 93
Study 27802097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxandrolone (Ox)
Number of subjects: 93
Study 26246443 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological modulation using selective antagonists for µ‐opioid, dopamine D3 receptor (DRD3), and neurokinin 1 (NK1) receptors (naltrexone, GSK598809, vofopitant/aprepitant) in a placebo-controlled, randomised, crossover design.
Number of subjects: 155